# US 2020/0368315 A1 · Antimicrobial peptides and admixtures thereof showing antimicrobial activity against gram-negative pathogens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368315 A1
- Document ID: US20200368315A1
- Status: Published application
- Kind: A1
- Application number: 16/622,533
- Filed: 2018-06-13
- Published: 2020-11-26
- Earliest claimed: 2017-06-13
- Assignees: Rijksuniversiteit Groningen
- Applicants: Rijksuniversiteit Groningen
- Inventors: Qian LI; Oscar Paul KUIPERS
- Web page: https://patentgrep.com/patent/US20200368315A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/164: {from bacteria}
- A61K 38/1729: {Cationic antimicrobial peptides, e.g. defensins}
- A61K 38/1767: {from invertebrates}
- A61P 31/04: Antibacterial agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to the field of medicine and microbiology, more specifically to means and methods for the treatment of infections caused by Gram-negative pathogens, in particular those showing or being prone to developing drug resistance. Provided is an admixture of (i) an inner membrane acting compound having membrane-permeating activity and/or lipid H binding activity; and (ii) one or more antimicrobial peptide(s) selected from the group consisting of RRLFRRIRWL-NH2 (GNP-6); GNNRPVYIPQPRPPHPRL (GNP-1); RIWVIWRR—NH2 (GNP-5); GIGKHVGKALKGLKGLLKGLGEC (GNP-7); and Xi X2IVQRIKKWLX3-NH2, wherein Xi is absent or K; X2 is R, K or A; and X3 is absent or R; wherein said one or more antimicrobial peptide(s) may comprise or consist of D- or L-amino acids.

## Claims

### Claim 1

An admixture of
(i) an inner membrane acting compound having membrane-permeating activity and/or lipid II binding activity; and
(ii) one or more antimicrobial peptide(s) selected from the group consisting of
(SEQ ID NO: 3)
RRLFRRILRWL-NH2 (GNP-6);
(SEQ ID NO: 1)
GNNRPVYIPQPRPPHPRL (GNP-1);
(SEQ ID NO: 2)
RIWVIWRR-NH2 (GNP-5);
(SEQ ID NO: 4)
GIGKHVGKALKGLKGLLKGLGEC (GNP-7);
and
(SEQ ID NO: 24)
X1X2IVQRIKKWLX3-NH2,
wherein X1 is absent or K
X2 is R, K or A
X3 is absent or R;
wherein said one or more antimicrobial peptide(s) may comprise or consist of D- or L-amino acids.

### Claim 2 (depends on 1)

Admixture according to claim 1, wherein the antimicrobial peptide is selected from the group consisting of
(SEQ ID NO: 3)
RRLFRRILRWL-NH2 (GNP-6)
(SEQ ID NO: 4)
GIGKHVGKALKGLKGLLKGLGEC (GNP-7)
(SEQ ID NO: 15)
RIVQRIKKWLR-NH2 (GNP-8)
(SEQ ID NO: 17)
RIVQRIKKWL-NH2 (GNP-8.1)
(SEQ ID NO: 18)
KIVQRIKKWLR-NH2 (GNP-8.2)
(SEQ ID NO: 19)
AIVQRIKKWLR-NH2 (GNP-8.3);
and
(SEQ ID NO: 16)
KRIVQRIKKWLR-NH2 (GNP-9).

### Claim 3 (depends on 1)

Admixture according to claim 1, wherein the one or more antimicrobial peptide(s) consists of L-amino acids.

### Claim 4 (depends on 1)

Admixture according to claim 1, wherein the one or more antimicrobial peptide(s) consists of D-amino acids.

### Claim 5 (depends on 1)

Admixture according to claim 1, wherein the antimicrobial peptide is selected from the group consisting of RRLFRRILRWL-NH2 (GNP-6) (SEQ ID NO: 3), RIVQRIKKWLR-NH2 (GNP-8) (SEQ ID NO: 15), RIVQRIKKWL-NH2 (GNP-8.1) (SEQ ID NO: 17), KIVQRIKKWLR-NH2 (GNP-8.2) (SEQ ID NO: 18), AIVQRIKKWLR-NH2 (GNP-8.3) (SEQ ID NO:19) and KRIVQRIKKWLR-NH2 (GNP-9) (SEQ ID NO:16).

### Claim 6 (depends on 5)

Admixture according to claim 5, wherein the antimicrobial peptide is RRLFRRILRWL-NH2 (GNP-6) (SEQ ID NO:3) or RIVQRIKKWLR-NH2 (GNP-8) (SEQ ID NO:15) comprising or consisting of D- or L-amino acids.

### Claim 7 (depends on 1)

Admixture according to claim 1, wherein the inner membrane acting compound is an inner membrane acting polypeptide.

### Claim 8 (depends on 7)

Admixture according to claim 7, wherein the inner membrane acting polypeptide is nisin or vancomycin.

### Claim 9 (depends on 1)

Admixture according to claim 1, wherein the inner membrane acting compound belongs to the group of macrolides.

### Claim 10

Antimicrobial peptide of the sequence X2IVQRIKKWLX3—NH2 (SEQ ID NO:15) wherein X2 is R, K or A; and X3 is absent or R, comprising or consisting of D- or L-amino acids.

### Claim 11 (depends on 10)

Antimicrobial peptide according to claim 10 of the sequence RIVQRIKKWLR-NH2 (GNP-8) (SEQ ID NO: 15), RIVQRIKKWL-NH2 (GNP-8.1) (SEQ ID NO. 17), KIVQRIKKWLR-NH2 (GNP-8.2) or AIVQRIKKWLR-NH2 (GNP-8.3) (SEQ ID NO:19), comprising or consisting of D- or L-amino acids.

### Claim 12 (depends on 10)

A bactericidal composition comprising a peptide according to claim 10, optionally comprising one or more further antimicrobial agent(s), and excipients.

### Claim 13 (depends on 1)

A pharmaceutical composition comprising an admixture according to claim 1, and a pharmaceutically acceptable vehicle, carrier or diluent.

### Claim 14 (depends on 13)

A composition according to claim 13, for use in a method of preventing or treating a pathogenic infection caused by a Gram-negative pathogen in a subject.

### Claim 15 (depends on 14)

Composition for use according to claim 14, wherein said infection is caused by a bacterium selected from the group consisting of E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii, Enterobacter cloaceae and Salmonella enterica.

### Claim 16

A method to enhance the therapeutic potential and efficacy of an inner membrane acting compound against a Gram-negative pathogen, comprising contacting said inner membrane acting compound with said Gram-negative pathogen in the presence of an antimicrobial peptide selected from the group consisting of
(SEQ ID NO: 3)
RRLFRRILRWL-NH2 (GNP-6)
(SEQ ID NO: 1)
GNNRPVYIPQPRPPHPRL (GNP-1)
(SEQ ID NO: 2)
RIWVIWRR-NH2 (GNP-5)
(SEQ ID NO: 4)
GIGKHVGKALKGLKGLLKGLGEC (GNP-7)
(SEQ ID NO: 15)
RIVQRIKKWLR-NH2 (GNP-8)
(SEQ ID NO: 17)
RIVQRIKKWL-NH2 (GNP-8.1)
(SEQ ID NO: 18)
KIVQRIKKWLR-NH2 (GNP-8.2)
(SEQ ID NO: 19)
AIVQRIKKWLR-NH2 (GNP-8.3);
and
(SEQ ID NO: 16)
KRIVQRIKKWLR-NH2 (GNP-9),
wherein said antimicrobial peptide comprises or consist of D- or L-amino acids.

### Claim 17 (depends on 16)

Method according to claim 16, wherein said inner membrane compound is nisin or vancomycin, or an active mutant or derivative thereof according to Table 2 or 3.
